Everest Medicines Secures Exclusive Rights to VIS‑101 in Greater China, Potential 2026 Phase 3 Launch
Hong Kong‑listed Everest Medicines Limited (HKG: 1952) today announced a strategic agreement with Visara, Inc.,...
HKG: 1952
I‑Mab Announces Global Transformation, NovaBridge Rebranding, and $37 M Acquisition of VIS‑101
I‑MAB Biopharma (NASDAQ: IMAB), a public company under the CBC Group, today revealed a strategic...
Everest Medicines Commences Global Phase I Trial of Universal mRNA Cancer Vaccine EVM14
Everest Medicines Limited (HKG: 1952) announced today that the first patient has been successfully dosed...
Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14
Everest Medicines Limited (HKG: 1952) announced today that the National Medical Products Administration (NMPA) has...
Everest Medicines Reports 48 % YoY Revenue Growth, NEFECON Launches, and VELSIPITY Production Milestone
Everest Medicines Limited (HKG: 1952) released unaudited interim financial results for the six months ended...
Everest Medicines’ Velsipity NDA Accepted for Review in Taiwan
China-based Everest Medicines (HKG: 1952) announced that the New Drug Application (NDA) for its Velsipity...
Everest Medicines’ Nefecon Granted Full Approval by Taiwan’s TFDA for IgA Nephropathy
China-based Everest Medicines (HKG: 1952) announced today that the Taiwan Food and Drug Administration (TFDA)...
Everest Medicines Completes HK$1.57 Billion Share Placement to Advance R&D and Commercialization
China-based Everest Medicines (HKG: 1952) announced today the completion of a share placement of 22,561,000...
Everest Medicines’ Nefecon Receives Full Approval from NMPA for IgAN Treatment
China-based Everest Medicines (HKG: 1952) announced that the National Medical Products Administration (NMPA) has converted...
Everest Medicines Reports Surge in Revenue, Advances Core Products and R&D Pipeline
China-based Everest Medicines (HKG: 1952) has announced its 2024 financial results, marking a significant milestone...
Everest Medicines’ EVM14 mRNA Cancer Vaccine Clears US FDA IND Application
China-based Everest Medicines (HKG: 1952) has announced that its Investigational New Drug (IND) application for...
Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production
China-based Everest Medicines (HKG: 1952) announced the start of construction for a manufacturing plant in...
Everest Medicines Begins Clinical Trial for Personalized mRNA Cancer Vaccine EVM16
China-based Everest Medicines (HKG: 1952) has announced the first patient dosing of an investigator-initiated clinical...
Everest Medicines’ Nefecon Receives First Prescription for IgAN Treatment in Adults
China-based Everest Medicines (HKG: 1952) has announced that its targeted-release budesonide, Nefecon, has been prescribed...
Everest Medicines’ Velsipity (Etrasimod) Receives First Prescription in Foshan under GBA Policy
Everest Medicines (HKG: 1952), a leading biopharmaceutical company based in China, has announced that its...
Everest Medicines’ Velsipity NDA for Ulcerative Colitis Accepted by China’s NMPA
China-based Everest Medicines (HKG: 1952) has announced that the National Medical Products Administration (NMPA) has...
Everest Medicines’ Nefecon Receives Full Approval from South Korea’s MFDS for IgAN Treatment
China-based Everest Medicines (HKG: 1952) has announced that it has received full approval from the...
Everest Medicines’ Velsipity Approved for Use in Select Hospitals in China’s Greater Bay Area
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received approval...
Everest Medicines’ Nefecon Approved in Taiwan for Primary IgAN Treatment
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received market...
Everest Medicines Reports 158% Revenue Growth in 2024 H1, Driven by Pharmaceutical Sales and Operational Efficiency
Everest Medicines, a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1952),...